Amgen's Ofman On Value-Based Contracts And Reimbursement Challenges
Amgen has negotiated 75 value-based contracts – agreements that SVP Josh Ofman sees as one area where biopharma and payer views are aligned. However, tension between the two sides remains high in pricing and reimbursement negotiations when it comes to rebates and other issues.
You may also be interested in...
Pharma company executives have limited experience with value-based contracts, but those that have experience are happy with them, says a new PwC report.
Celgene, Express Scripts, and Aetna discuss need for shared accountability, data sharing and value assessment at DIA meeting.
The Institute for Clinical and Economic Review is lowering the value-based pricing benchmark for Amgen's PCSK9 inhibitor based on the results of the FOURIER cardiovascular outcomes trial – which was positive overall but did not show a reduction in CV mortality.